<DOC>
	<DOCNO>NCT02690181</DOCNO>
	<brief_summary>The objective extension study initial assessment safety immunogenicity second dose GBS Trivalent Vaccine follow time interval close inter-pregnancy interval observe general population .</brief_summary>
	<brief_title>Extension Study Evaluate Immunogenicity Safety Second Dose GBS Trivalent Vaccine Healthy Non-Pregnant Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>1 . Healthy , nonpregnant subject receive single 5 µg dose GBS Trivalent Vaccine placebo V98_06 study healthy nonpregnant female subject age 2246 year inclusive day inform consent receive GBS vaccine past 2 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator 3 . Females childbearing potential use effective birth control method intend use end study ( day 181 visit ) females nonchildbearing potential 1 . Progressive , unstable uncontrolled clinical condition , clinical condition represent contraindication intramuscular vaccination blood draw 2 . Abnormal function immune system 3 . Received immunoglobulin blood product within 180 day prior inform consent 4 . Received investigational nonregistered medicinal product within 30 day prior inform consent 5 . Any clinical condition , opinion investigator , might interfere result study pose additional risk subject due participation study 6 . Individuals receive vaccine within 14 day inactivate vaccine 28 day live vaccine prior enrolment study plan receive vaccine within 28 day study vaccination . Exception inactivate influenza vaccine may administer 7 day prior study vaccination 7 day study vaccination 7 . Individuals anticipate become pregnant prior end study , individual breastfeed 8 . Individuals previous immunization vaccine contain Group B Streptococcus antigens part V98_06 study 9 . Individuals fever ( oral temperature ≥ 38°C ) within 3 day prior day 1 use antipyretic and/or analgesic medication within 24 hour prior day 1 10 . Individuals acute chronic infection ( ) require systemic antibiotic treatment antiviral therapy , within 7 day prior day 1</criteria>
	<gender>Female</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>46 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>